Rodolfo Bordoni, MD

Rodolfo Bordoni, MD, discusses the utility of ​atezolizumab in the adjuvant setting in non–small cell lung cancer.

Rodolfo Bordoni, MD, discusses the utility of ​adjuvant osimertinib in lung cancer.

Rodolfo Bordoni, MD, discusses the importance of the phase 1/2 LIBRETTO-001 trial with selpercatinib in patients with RET fusion–positive non–small cell lung cancer.